PCSA

PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117

Processa Set to Join Russell Microcap® Index

Processa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET

Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

Processa Pharmaceuticals, Inc. (PCSA) CEO David Young on Q1 2021 Results - Earnings Call Transcript

Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update